AMAG Updates Feraheme Label To Include Safety Risks
AMAG Pharmaceuticals Inc. has reached an agreement with the U.S. Food and Drug Administration to update the label for its injectable iron deficiency treatment Feraheme to include adverse reactions identified after...To view the full article, register now.
Already a subscriber? Click here to view full article